Captopril CAS 62571-86-2 API Factory USP High Quality Anti-Hypertension
Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Captopril
CAS: 62571-86-2
Active Angiotensin-Converting Enzyme (ACE) Inhibitor Anti-Hypertension
API High Quality, Commercial Production
| Chemical Name | Captopril |
| Synonyms | (S)-(-)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; (S)-(-)-1-(3-Mercapto-2-methylpropionyl)-L-proline |
| CAS Number | 62571-86-2 |
| CAT Number | RF-API89 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C9H15NO3S |
| Molecular Weight | 217.29 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Assay | 98.0%~102.0% (on dried basis) |
| Melting Point | 104.0~110.0℃ |
| Specific Optical Rotation | -125.0° to -134.0° |
| Acidity | 7.0~8.0 |
| Loss on Drying | ≤1.0% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Related Substances | |
| Captopril Disulfide | ≤1.0% |
| Single Unknown Impurity | ≤0.20% |
| Total Impurities | ≤0.50% |
| Organic Volatile Impurities | Meets the Requirements |
| Test Standard | Enterprise Standard |
| Usage | Used as Anti-Hypertension Medicament |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Captopril is the most studied of the angiotensin-converting enzyme (ACE) inhibitors proposed as an antihypertensive drug. It blocks angiotensin-converting enzyme, which suppresses formation of angiotensin II and relieves its vasoconstricting effect on arterial and venous vessels. Overall vascular peripheral tension is reduced, which results in the lowering of arterial pressure. Captopril, as well as other ACE inhibitors, is indicated in the treatment of hypertension, congestive heart failure, left ventricular dysfunction after a myocardial infarction, and diabetic nephropathy. In the treatment of essential hypertension, captopril is considered firstchoice therapy, either alone or in combination with a thiazide diuretic. Decreases in blood pressure are primarily attributed to decreased total peripheral resistance or afterload. An advantage of combining captopril therapy with a conventional thiazide diuretic is that the thiazide-induced hypokalemia is minimized in the presence of ACE inhibition, since there is a marked decrease in angiotensin II–induced aldosterone release.
